{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T09:04:39Z","timestamp":1774256679098,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100017661","name":"China Health Promotion Foundation","doi-asserted-by":"publisher","award":["YXTJ-2023-0638-0045"],"award-info":[{"award-number":["YXTJ-2023-0638-0045"]}],"id":[{"id":"10.13039\/501100017661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019000","name":"Medical Affairs Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvir.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jvir.2026.108001","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:38:08Z","timestamp":1768610288000},"page":"108001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bronchial Arterial Chemoembolization Combined with Tislelizumab for Non\u2013Small Cell Lung Cancer: An Exploratory, Prospective, Single-Arm, Phase II Trial"],"prefix":"10.1016","volume":"37","author":[{"given":"Chao","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daqian","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manzhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglin","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haolin","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huibin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhuang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9594-0198","authenticated-orcid":false,"given":"Xuhua","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2026.108001_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jvir.2026.108001_bib2","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jvir.2026.108001_bib3","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.3390\/cells11203200","article-title":"Biomarker-targeted therapies in non-small cell lung cancer: current status and perspectives","volume":"11","author":"Guo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jvir.2026.108001_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jvir.2026.108001_bib5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.lungcan.2020.06.010","article-title":"Combination of computed tomography-guided iodine-125 brachytherapy and bronchial arterial chemoembolization for locally advanced stage III non-small cell lung cancer after failure of concurrent chemoradiotherapy","volume":"146","author":"Chen","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jvir.2026.108001_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000807","article-title":"Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma","volume":"8","author":"He","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jvir.2026.108001_bib7","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.21037\/qims-23-287","article-title":"Drug-eluting beads bronchial arterial chemoembolization\/bronchial arterial infusion chemotherapy with and without PD-1 blockade for advanced non-small cell lung cancer: a comparative single-center cohort study","volume":"13","author":"Xu","year":"2023","journal-title":"Quant Imaging Med Surg"},{"key":"10.1016\/j.jvir.2026.108001_bib8","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jvir.2021.08.019","article-title":"Sintilimab plus bronchial arterial infusion chemotherapy\/drug-eluting embolic chemoembolization for advanced non-small cell lung cancer: a preliminary study of 10 patients","volume":"32","author":"Li","year":"2021","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2026.108001_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.crad.2025.106849","article-title":"Clinical outcomes, toxic effect, and immune microenvironment changes of drug-eluting bead bronchial arterial chemoembolisation\/bronchial arterial chemoembolization combined with immunotherapy in treating elderly patients with non-small cell lung cancer","volume":"84","author":"Xiang","year":"2025","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jvir.2026.108001_bib10","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jvir.2026.108001_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","article-title":"Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis","volume":"28","author":"Dahan","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jvir.2026.108001_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jtho.2022.09.217","article-title":"Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): a phase 3, open-label, randomized controlled trial","volume":"18","author":"Zhou","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jvir.2026.108001_bib13","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial","volume":"16","author":"Lu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jvir.2026.108001_bib14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jvir.2026.108001_bib15","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1111\/1759-7714.13139","article-title":"The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer","volume":"10","author":"Bie","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jvir.2026.108001_bib16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.lungcan.2012.04.006","article-title":"Prospective study of transarterial infusion of docetaxel and cisplatin to treat non-small-cell lung cancer in patients contraindicated for standard chemotherapy","volume":"77","author":"Nakanishi","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jvir.2026.108001_bib17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11547-016-0629-2","article-title":"Transcatheter arterial chemical infusion for advanced non-small-cell lung cancer: long-term outcome and predictor of survival","volume":"121","author":"Fu","year":"2016","journal-title":"Radiol Med"},{"key":"10.1016\/j.jvir.2026.108001_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/1753465817717169","article-title":"Neoadjuvant chemotherapy by bronchial arterial infusion in patients with unresectable stage III squamous cell lung cancer","volume":"11","author":"Zhu","year":"2017","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jvir.2026.108001_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103728","article-title":"Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial)","volume":"9","author":"Lu","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.jvir.2026.108001_bib20","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.acra.2022.01.015","article-title":"The efficacy of drug-eluting bead transarterial chemoembolization loaded with oxaliplatin for the treatment of stage III-IV non-small-cell lung cancer","volume":"29","author":"Ren","year":"2022","journal-title":"Acad Radiol"},{"key":"10.1016\/j.jvir.2026.108001_bib21","article-title":"Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on quality of life: a multicenter prospective study","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jvir.2026.108001_bib22","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2026.108001_bib23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvir.2026.108001_bib24","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2026.108001_bib25","first-page":"3453","article-title":"Toxicity and quality of life in published clinical trials for advanced lung cancer","volume":"26","author":"Zwitter","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jvir.2026.108001_bib26","first-page":"2554","article-title":"Drug-eluting bead bronchial arterial chemoembolization vs. chemotherapy in treating advanced non-small cell lung cancer: comparison of treatment efficacy, safety and quality of life","volume":"25","author":"Liu","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jvir.2026.108001_bib27","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0717","article-title":"Phase II study on biweekly combination therapy of gemcitabine plus carboplatin for the treatment of elderly patients with advanced non-small cell lung cancer","volume":"25","author":"Takayama","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jvir.2026.108001_bib28","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1080\/13543784.2020.1833857","article-title":"Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)","volume":"29","author":"Liu","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jvir.2026.108001_bib29","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1186\/s12885-025-13949-9","article-title":"Bronchial arterial chemoembolization\/infusion combined with iodine-125 brachytherapy in advanced non-small cell lung cancer: a promising salvage therapy after standard treatment failure","volume":"25","author":"Tang","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jvir.2026.108001_bib30","article-title":"Clinical study on bronchial artery chemoembolization for unresectable non-small cell lung cancer","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.jvir.2026.108001_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00276-017-1918-8","article-title":"An applied anatomical study of bronchial artery","volume":"40","author":"Fei","year":"2018","journal-title":"Surg Radiol Anat"},{"key":"10.1016\/j.jvir.2026.108001_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.carj.2014.07.001","article-title":"The normal anatomy and variations of the bronchial arteries: evaluation with multidetector computed tomography","volume":"66","author":"Yener","year":"2015","journal-title":"Can Assoc Radiol J"},{"key":"10.1016\/j.jvir.2026.108001_bib33","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/1759-7714.13522","article-title":"Clinical effect of bronchial arterial infusion chemotherapy and CalliSpheres drug-eluting beads in patients with stage II-IV lung cancer: a prospective cohort study","volume":"11","author":"Shang","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jvir.2026.108001_bib34","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.2217\/fon-2021-1515","article-title":"Efficacy and safety of drug-eluting beads bronchial arterial chemoembolization versus conventional bronchial arterial chemoembolization in lung cancer patients with hemoptysis","volume":"18","author":"Fu","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.jvir.2026.108001_bib35","article-title":"Efficacy and safety of drug-eluting bead bronchial arterial chemoembolization plus anlotinib in patients with advanced non-small-cell lung cancer","volume":"9","author":"Liu","year":"2021","journal-title":"Front Cell Dev Biol"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044326000126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044326000126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:24:46Z","timestamp":1774254286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051044326000126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1051044326000126"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2026.108001","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bronchial Arterial Chemoembolization Combined with Tislelizumab for Non\u2013Small Cell Lung Cancer: An Exploratory, Prospective, Single-Arm, Phase II Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2026.108001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier, Inc., on behalf of SIR.","name":"copyright","label":"Copyright"}],"article-number":"108001"}}